Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma

Journal of Clinical Oncology

Volumn 30, Issue 16, 2012, Pages 1966-1973

  Callens, Celine ^a,b   Baleydier, Frederic ^e   Lengline, Etienne ^a,b   Ben Abdelali, Raouf ^a,b   Petit, Arnaud ^c   Villarese, Patrick ^b   Cieslak, Agata ^b   Minard Colin, Veronique ^f   Rullier, Anne ^g   Moreau, Anne ^h   Baruchel, André ^d   Schmitt, Claudine ⁱ   Asnafi, Vahid ^a,b   Bertrand, Yves ^e   Macintyre, Elizabeth ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e UNIVERSITÉ LYON 1   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8 ASSOCIATED PROTEIN 2; DEXAMETHASONE; DNA; GLUCOCORTICOID; MESSENGER RNA; MOLECULAR MARKER; NOTCH1 RECEPTOR; PREDNISONE; RAPAMYCIN; RECEPTOR SUBTYPE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CHROMOSOME 6Q; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GENE DELETION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; IMMUNOPHENOTYPING; INFANT; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; T CELL LYMPHOBLASTIC LYMPHOMA; T CELL LYMPHOMA; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADOLESCENT; APOPTOSIS REGULATORY PROTEINS; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CHILD; CHILD, PRESCHOOL; F-BOX PROTEINS; FEMALE; HUMANS; INFANT; MALE; MUTATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECEPTOR, NOTCH1; RECEPTORS, ANTIGEN, T-CELL; SEQUENCE DELETION; UBIQUITIN-PROTEIN LIGASES;

EID: 84863975116     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.7661     Document Type: Article

References (36)

1. Feng H, Stachura DL, White RM, et al: T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell 18:353-366, 2010
2. Campana D, Coustan-Smith E: Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol 112:8-15, 2004 (Pubitemid 38716244)
3. Flohr T, Schrauder A, Cazzaniga G, et al: Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 22:771-782, 2008 (Pubitemid 351552626)
4. Waanders E, van der Velden VH, van der Schoot CE, et al: Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 25:254-258, 2011
5. Coustan-Smith E, Sandlund JT, Perkins SL, et al: Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: A report from the Children's Oncology Group. J Clin Oncol 27:3533-3539, 2009
6. Aifantis I, Raetz E, Buonamici S: Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 8:380-390, 2008 (Pubitemid 351595220)
7. Gutierrez A, Dahlberg SE, Neuberg DS, et al: Absence of biallelic TCR-gamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol 28:3816-3823, 2010
8. Aster JC, Blacklow SC, Pear WS: Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 223:262-273, 2011
9. Weng AP, Ferrando AA, Lee W, et al: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306:269-271, 2004 (Pubitemid 39336870)
10. Malyukova A, Dohda T, von der Lehr N, et al: The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 67:5611-5616, 2007 (Pubitemid 46984990)
11. Breit S, Stanulla M, Flohr T, et al: Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 108:1151-1157, 2006 (Pubitemid 44232009)
12. Zhu YM, Zhao WL, Fu JF, et al: NOTCH1 mutations in T-cell acute lymphoblastic leukemia: Prognostic significance and implication in multifactorial leukemogenesis. Clin Cancer Res 12:3043-3049, 2006
13. van Grotel M, van den Heuvel-Eibrink MM, van Wering ER, et al: CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 51:737-740, 2008
14. Clappier E, Collette S, Grardel N, et al: NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 24:2023-2031, 2010
15. Kox C, Zimmermann M, Stanulla M, et al: The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 24:2005-2013, 2010
16. Zuurbier L, Homminga I, Calvert V, et al: NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 24:2014-2022, 2010
17. Asnafi V, Buzyn A, Le Noir S, et al: NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): A Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 113:3918-3924, 2009
18. Ben Abdelali R, Asnafi V, Leguay T, et al: Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: A GRAALL study. Blood 118:5099-5107, 2011
19. Baleydier F, Decouvelaere AV, Bergeron J, et al: T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res 14:692-700, 2008 (Pubitemid 351231149)
20. Park MJ, Taki T, Oda M, et al: FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 145:198-206, 2009
21. Burkhardt B, Bruch J, Zimmermann M, et al: Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia 20:1422-1429, 2006 (Pubitemid 44084056)
22. Burkhardt B, Moericke A, Klapper W, et al: Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma 49:451-461, 2008 (Pubitemid 351298328)
23. Jackson A, Carrara P, Duke V, et al: Deletion of 6q16-q21 in human lymphoid malignancies: A mapping and deletion analysis. Cancer Res 60:2775-2779, 2000 (Pubitemid 30395790)
24. Remke M, Pfister S, Kox C, et al: Highresolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. Blood 114:1053-1062, 2009
25. Alm-Kristiansen AH, Saether T, Matre V, et al: FLASH acts as a co-activator of the transcription factor c-Myb and localizes to active RNA polymerase II foci. Oncogene 27:4644-4656, 2008
26. Jun JI, Chung CW, Lee HJ, et al: Role of FLASH in caspase-8-mediated activation of NF-kappaB: Dominant-negative function of FLASH mutant in NF-kappaB signaling pathway. Oncogene 24:688-696, 2005
27. Reiter A, Schrappe M, Ludwig WD, et al: Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM group report. Blood 95:416-421, 2000 (Pubitemid 30041651)
28. Oschlies I, Burkhardt B, Chassagne-Clement C, et al: Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: Experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol 35:836-844, 2010
29. Murphy SB: Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: Dissimilarities from lymphomas in adults. Semin Oncol 7:332-339, 1980
30. Sulis ML, Williams O, Palomero T, et al: NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood 112:733-740, 2008
31. Iacobucci I, Storlazzi CT, Cilloni D, et al: Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: On behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114:2159-2167, 2009
32. Mullighan CG, Miller CB, Radtke I, et al: BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453:110-114, 2008 (Pubitemid 351630327)
33. Gu L, Zhou C, Liu H, et al: Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J Exp Clin Cancer Res 29:150, 2010
34. Batista A, Barata JT, Raderschall E, et al: Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol 39:457-472, 2011 (suppl e3)
35. Asnafi V, Beldjord K, Boulanger E, et al: Analysis of TCR, pT alpha, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood 101:2693-2703, 2003 (Pubitemid 36857632)
36. Coustan-Smith E, Mullighan CG, Onciu M, et al: Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10:147-156, 2009